ArticleThe Lancet regional health. Western Pacific2026
Long-term projections of cancer prevalence in Australia to 2050: a population-based statistical modelling study.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer prevalence is the number of people alive with a past cancer diagnosis in a specified number of previous years (e.g., last 5 or 30 years). This study estimates 1- to 30-year cancer prevalence in Australia for each year in 2025-2050, for 24 cancer types, the group of remaining cancers, and for all cancers combined. Methods: We used validated methods to estimate prevalence as a function of incidence and survival, using tabulated data from the Australian Institute of Health and Welfare and incorporating the effect of influential cancer-specific factors. The number of people living with cancer (cancers not yet cured) is estimated using the time-to-cure method. Findings: The 30-year prevalence is projected to increase by 57.1% from 1,666,020 (95% uncertainty interval [UI]: 1,553,825-1,784,900) in 2025 to 2,617,016 (95% UI: 2,333,949-2,947,174) in 2050. For people aged 80+ years, 30-year prevalence is projected to increase by 111.0% from 481,079 (95% UI: 448,799-515,286) in 2025 to 1,015,061 (95% UI: 917,670-1,125,036) in 2050. Breast cancer is projected to be the most prevalent cancer in Australia in 2050, followed by prostate, melanoma and colorectal cancer. For 30-year prevalence in 2050, 43.9% of people (1,149,364; 95% UI: 1,103,165-1,238,377) are estimated to be living with cancer (cancers not yet cured) and requiring initial treatment or ongoing care. Interpretation: A substantial increase in the number of people with a past cancer diagnosis in Australia is expected in 2025-2050. Expansion of appropriate services to meet the demand will be a key challenge for the health system in Australia. Funding: This work was not supported by a dedicated research grant. This work and open access publishing were supported by the Cancer Council NSW, through funding to the Daffodil Centre. KC is a recipient of a Fellowship from the National Health and Medical Research Council of Australia (APP1194679). JS is a recipient of a Cancer Institute NSW Career Development Fellowship (2022/CDF1154).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.